AMPLITUDE — Niraparib plus abiraterone acetate and prednisone versus placebo plus abiraterone acetate and prednisone in HRR-mutated metastatic castration-sensitive prostate cancer (AMPLITUDE)

Phase 3 · Prostate Cancer

Population

Homologous-recombination-repair (HRR) gene-mutated metastatic castration-sensitive prostate cancer.

Primary Endpoint

Radiographic progression-free survival

Rationale

PARP inhibitors benefit HRR-mutated castration-resistant prostate cancer, but their role in the earlier hormone-sensitive setting is unproven. AMPLITUDE tests whether adding niraparib to first-line hormonal therapy intensifies benefit for HRR-mutated disease.

What It Could Change

Could establish PARP-inhibitor intensification of hormonal therapy as a front-line standard for HRR-mutated metastatic castration-sensitive prostate cancer.